- Home
- ARMP vs KNDI Comparison
ARMP vs KNDI Comparison
Compare ARMP & KNDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- KNDI
- Stock Information
- Founded
- ARMP N/A
- KNDI 2002
- Country
- ARMP United States
- KNDI China
- Employees
- ARMP N/A
- KNDI N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- KNDI Auto Manufacturing
- Sector
- ARMP Health Care
- KNDI Consumer Discretionary
- Exchange
- ARMP Nasdaq
- KNDI Nasdaq
- Market Cap
- ARMP 92.4M
- KNDI 109.2M
- IPO Year
- ARMP N/A
- KNDI N/A
- Fundamental
- Price
- ARMP $2.86
- KNDI $1.37
- Analyst Decision
- ARMP Strong Buy
- KNDI
- Analyst Count
- ARMP 1
- KNDI 0
- Target Price
- ARMP $9.00
- KNDI N/A
- AVG Volume (30 Days)
- ARMP 12.1K
- KNDI 247.2K
- Earning Date
- ARMP 11-12-2025
- KNDI 08-19-2025
- Dividend Yield
- ARMP N/A
- KNDI N/A
- EPS Growth
- ARMP N/A
- KNDI N/A
- EPS
- ARMP N/A
- KNDI N/A
- Revenue
- ARMP $6,868,000.00
- KNDI $104,035,613.00
- Revenue This Year
- ARMP $8.43
- KNDI N/A
- Revenue Next Year
- ARMP N/A
- KNDI N/A
- P/E Ratio
- ARMP N/A
- KNDI N/A
- Revenue Growth
- ARMP 84.67
- KNDI N/A
- 52 Week Low
- ARMP $0.90
- KNDI $0.89
- 52 Week High
- ARMP $3.14
- KNDI $2.07
- Technical
- Relative Strength Index (RSI)
- ARMP 57.54
- KNDI 48.40
- Support Level
- ARMP $2.79
- KNDI $1.34
- Resistance Level
- ARMP $3.03
- KNDI $1.45
- Average True Range (ATR)
- ARMP 0.16
- KNDI 0.08
- MACD
- ARMP 0.01
- KNDI -0.02
- Stochastic Oscillator
- ARMP 62.16
- KNDI 12.50
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About KNDI Kandi Technologies Group Inc
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.